Oryzon Genomics S.A. Logo

Oryzon Genomics S.A.

0RDB.L

(2.0)
Stock Price

1,67 EUR

-3.65% ROA

-4.85% ROE

-30.01x PER

Market Cap.

127.423.173,83 EUR

24.92% DER

0% Yield

0% NPM

Oryzon Genomics S.A. Stock Analysis

Oryzon Genomics S.A. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Oryzon Genomics S.A. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (49.88%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

3 PBV

The stock's low PBV ratio (-13.03x) suggests it's undervalued, making it an attractive opportunity for investors.

4 DER

The stock has a low debt to equity ratio (-108%), which means it has a small amount of debt compared to the ownership it holds

5 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

6 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

7 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (-8), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Oryzon Genomics S.A. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Oryzon Genomics S.A. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Buy

Oryzon Genomics S.A. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Oryzon Genomics S.A. Revenue
Year Revenue Growth
2012 4.353.456
2013 3.250.601 -33.93%
2014 18.805.646 82.71%
2015 7.802.989 -141.01%
2016 5.272.470 -47.99%
2017 5.179.650 -1.79%
2018 7.768.147 33.32%
2019 11.528.474 32.62%
2020 11.630.980 0.88%
2021 12.081.983 3.73%
2022 16.809.390 28.12%
2023 0 0%
2023 0 0%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Oryzon Genomics S.A. Research and Development Expenses
Year Research and Development Expenses Growth
2012 454.822
2013 1.742.700 73.9%
2014 6.950.199 74.93%
2015 6.833.995 -1.7%
2016 7.755.395 11.88%
2017 7.602.159 -2.02%
2018 4.699.278 -61.77%
2019 5.404.374 13.05%
2020 5.960.175 9.33%
2021 8.370.134 28.79%
2022 7.099.261 -17.9%
2023 16.122.184 55.97%
2023 16.631.000 3.06%
2024 9.300.000 -78.83%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Oryzon Genomics S.A. General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 0
2013 0 0%
2014 0 0%
2015 1.855 100%
2016 2.167 14.4%
2017 0 0%
2018 666 100%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 4.509.932 100%
2023 4.247.000 -6.19%
2024 4.888.000 13.11%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Oryzon Genomics S.A. EBITDA
Year EBITDA Growth
2012 141.209
2013 -932.345 115.15%
2014 12.225.308 107.63%
2015 -548.788 2327.69%
2016 -5.017.927 89.06%
2017 -5.480.799 8.45%
2018 -3.548.129 -54.47%
2019 -4.145.969 14.42%
2020 -5.079.353 18.38%
2021 -7.830.657 35.14%
2022 -5.728.975 -36.69%
2023 -20.485.288 72.03%
2023 -20.715.965 1.11%
2024 14.640.000 241.5%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Oryzon Genomics S.A. Gross Profit
Year Gross Profit Growth
2012 3.941.934
2013 2.998.386 -31.47%
2014 18.392.884 83.7%
2015 7.414.694 -148.06%
2016 4.882.012 -51.88%
2017 4.853.331 -0.59%
2018 7.432.869 34.7%
2019 11.045.974 32.71%
2020 10.987.985 -0.53%
2021 11.232.932 2.18%
2022 16.312.410 31.14%
2023 0 0%
2023 0 0%
2024 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Oryzon Genomics S.A. Net Profit
Year Net Profit Growth
2012 -608.292
2013 -2.972.730 79.54%
2014 8.049.995 136.93%
2015 -1.077.277 847.25%
2016 -5.734.403 81.21%
2017 -6.235.343 8.03%
2018 -1.348.399 -362.43%
2019 -4.133.268 67.38%
2020 -4.152.892 0.47%
2021 -5.334.589 22.15%
2022 -4.530.895 -17.74%
2023 -6.534.424 30.66%
2023 -3.705.000 -76.37%
2024 452.000 919.69%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Oryzon Genomics S.A. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 0
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Oryzon Genomics S.A. Free Cashflow
Year Free Cashflow Growth
2012 0
2013 0 0%
2014 14.620.133 100%
2015 472.973 -2991.11%
2016 -5.300.269 108.92%
2017 -5.774.336 8.21%
2018 -957.409 -503.12%
2019 -4.542.176 78.92%
2020 -6.071.292 25.19%
2021 -4.327.114 -40.31%
2022 -2.059.293 -110.13%
2023 0 0%
2023 0 0%
2024 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Oryzon Genomics S.A. Operating Cashflow
Year Operating Cashflow Growth
2012 0
2013 0 0%
2014 14.677.385 100%
2015 568.168 -2483.28%
2016 -5.270.288 110.78%
2017 -5.648.344 6.69%
2018 -763.077 -640.21%
2019 -4.412.809 82.71%
2020 -5.884.774 25.01%
2021 -4.127.498 -42.57%
2022 -1.978.348 -108.63%
2023 0 0%
2023 0 0%
2024 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Oryzon Genomics S.A. Capital Expenditure
Year Capital Expenditure Growth
2012 0
2013 0 0%
2014 57.251 100%
2015 95.194 39.86%
2016 29.981 -217.51%
2017 125.992 76.2%
2018 194.332 35.17%
2019 129.367 -50.22%
2020 186.518 30.64%
2021 199.615 6.56%
2022 80.946 -146.61%
2023 0 0%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Oryzon Genomics S.A. Equity
Year Equity Growth
2012 -1.814.480
2013 20.282.071 108.95%
2014 16.816.670 -20.61%
2015 29.967.903 43.88%
2016 23.922.512 -25.27%
2017 41.310.161 42.09%
2018 51.695.716 20.09%
2019 68.568.578 24.61%
2020 92.756.891 26.08%
2021 81.108.615 -14.36%
2022 77.708.642 -4.38%
2023 85.699.852 9.32%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Oryzon Genomics S.A. Assets
Year Assets Growth
2012 0
2013 39.609.679 100%
2014 31.541.194 -25.58%
2015 44.236.644 28.7%
2016 52.356.834 15.51%
2017 73.237.836 28.51%
2018 77.271.866 5.22%
2019 89.842.611 13.99%
2020 114.960.000 21.85%
2021 108.564.000 -5.89%
2022 111.039.000 2.23%
2023 114.180.000 2.75%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Oryzon Genomics S.A. Liabilities
Year Liabilities Growth
2012 12.351.551
2013 19.327.608 36.09%
2014 14.724.524 -31.26%
2015 14.268.740 -3.19%
2016 28.434.321 49.82%
2017 31.927.674 10.94%
2018 25.576.149 -24.83%
2019 21.274.032 -20.22%
2020 22.203.703 4.19%
2021 27.455.486 19.13%
2022 33.330.933 17.63%
2023 28.481.141 -17.03%

Oryzon Genomics S.A. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.07
Price to Earning Ratio
-30.01x
Price To Sales Ratio
0x
POCF Ratio
0
PFCF Ratio
0
Price to Book Ratio
1.45
EV to Sales
0
EV Over EBITDA
-37.79
EV to Operating CashFlow
0
EV to FreeCashFlow
0
Earnings Yield
-0.03
FreeCashFlow Yield
0
Market Cap
0,13 Bil.
Enterprise Value
0,13 Bil.
Graham Number
1.44
Graham NetNet
-0.22

Income Statement Metrics

Net Income per Share
-0.07
Income Quality
0
ROE
-0.05
Return On Assets
-0.04
Return On Capital Employed
-0.17
Net Income per EBT
1
EBT Per Ebit
0.25
Ebit per Revenue
0
Effective Tax Rate
-1.42

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0
Free CashFlow per Share
0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-0.38
Return on Tangible Assets
-0.04
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,24
Book Value per Share
1,38
Tangible Book Value per Share
1.37
Shareholders Equity per Share
1.38
Interest Debt per Share
0.34
Debt to Equity
0.25
Debt to Assets
0.19
Net Debt to EBITDA
-1.89
Current Ratio
1.21
Tangible Asset Value
0,09 Bil.
Net Current Asset Value
-0,01 Bil.
Invested Capital
4656318
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.17

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Oryzon Genomics S.A. Dividends
Year Dividends Growth
2022 0

Oryzon Genomics S.A. Profile

About Oryzon Genomics S.A.

Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.

CEO
Dr. Carlos Manuel Buesa Arjol
Employee
44
Address
Sant Ferran 74
Cornellà de Llobregat, 08940

Oryzon Genomics S.A. Executives & BODs

Oryzon Genomics S.A. Executives & BODs
# Name Age
1 Dr. Carlos Manuel Buesa Arjol
Co-Founder, Chairman, Chief Executive Officer & President
70
2 Mr. Emili Torrell Cortada
Chief Business Development Officer
70
3 Mr. Augusto Pinel Rubio
Secretary
70
4 Mr. Enric Rello Condomines
Director of Operations, Chief Operating Officer & Chief Financial Officer
70
5 Mr. Jordi Xaus Pey
Chief Scientific Officer
70
6 Mr. Xavier Perpinya Ribera
Head of Internal Audit & Compliance
70
7 Ms. Neus Virgili Bernado
Chief Intellectual Property Officer
70
8 Dr. Michael Thomas Ropacki Ph.D.
Chief Medical Officer of CNS
70
9 Ms. Sonia Paloma Gutierrez Bezon
Chief of Clinical Operations
70

Oryzon Genomics S.A. Competitors